Novanta

US · NOVT #1995 by market cap Listed 1970

143.64 -5.46 -3.66%

Live - 5344 symbols - heartbeat 554s ago · 2026-10-08 07:14

Pre-market 137.16 -4.51%

After-hours 143.64 0.00%

Overnight 143.00 -0.45%

Market cap: 5.43B
P/E (TTM): 90.91
P/B: 3.36
EPS: 1.47
Div yield: 0.00%
52W pos: 58%

Reader sentiment Are you bullish or bearish on NOVT?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Financial Health how this is computed

Good

Altman Z-Score is 8.00, above the 3.0 "safe zone" threshold.
Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Revenue annual, last 8 years

Latest year +3.30% YoY

Margins

Gross margin: 44.39%
Operating margin: 11.90%
Net margin: 5.49%

Key ratios & quality

Enterprise value: 5.31B
Altman Z-Score: 8.00

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	614.34M	626.10M	590.62M	706.79M	860.90M	881.66M	949.25M	980.60M
Gross profit	261.53M	262.09M	244.52M	300.33M	378.47M	399.90M	421.55M	435.28M
Selling & admin expenses	115.90M	118.41M	109.85M	129.16M	158.90M	164.46M	175.94M	195.66M
Research & development	51.02M	55.97M	61.00M	72.52M	85.77M	91.68M	95.52M	95.48M
Operating profit	79.05M	71.86M	59.70M	82.07M	107.46M	123.31M	124.29M	116.66M
Pretax profit	61.30M	45.77M	48.40M	56.17M	87.16M	83.75M	79.07M	69.64M
Tax	10.21M	4.99M	3.88M	5.84M	13.11M	10.87M	14.98M	15.81M
Net profit	51.10M	40.77M	44.52M	50.33M	74.05M	72.88M	64.09M	53.83M
Basic EPS	1	1	1	1	2	2	2	1
Diluted EPS	1.43	1.15	1.25	1.41	2.06	2.02	1.77	1.47

Line item	2025-03	2025-06	2025-09	2025-12	2026-04	2026-07
Revenue	233.37M	241.05M	247.84M	258.35M	257.71M	265.81M
Gross profit	104.35M	106.75M	110.92M	113.26M	113.58M	120.92M
Selling & admin expenses	45.60M	47.10M	51.38M	51.58M	54.41M	59.97M
Research & development	23.24M	25.29M	24.09M	22.87M	23.25M	23.97M
Operating profit	29.97M	27.48M	28.53M	30.69M	30.14M	30.56M
Pretax profit	26.42M	5.79M	15.76M	21.68M	26.35M	15.90M
Tax	5.21M	1.29M	5.11M	4.21M	5.26M	3.36M
Net profit	21.21M	4.50M	10.65M	17.47M	21.10M	12.54M
Basic EPS	1	0	0	0	1	0
Diluted EPS	0.59	0.12	0.30	0.45	0.51	0.30

Balance sheet

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Total current assets	281.77M	304.51M	304.17M	373.83M	420.52M	415.30M	433.65M	782.60M
Cash & ST investments	82.04M	78.94M	125.05M	117.39M	100.11M	105.05M	113.99M	380.87M
Inventory	104.76M	116.62M	92.74M	125.66M	168.00M	149.37M	144.61M	188.28M
Total assets	719.58M	869.74M	865.18M	1.23B	1.24B	1.23B	1.39B	1.81B
Total current liabilities	104.20M	134.85M	114.23M	183.94M	164.52M	139.18M	167.79M	212.37M
Short-term debt	4.54M	11.38M	21.42M	13.03M	13.26M	13.88M	14.57M	48.15M
Long-term debt	202.84M	215.33M	194.93M	429.36M	430.66M	349.40M	411.95M	212.54M
Total liabilities	351,321,000.00	452,564,000.00	388,370,000.00	706,592,000.00	663,626,000.00	552,596,000.00	642,813,000.00	492,819,000.00
Total equity	368.26M	417.17M	476.81M	521.29M	577.59M	673.46M	745.70M	1.31B
Retained earnings	-79.09M	-38.32M	6.20M	56.53M	130.58M	203.46M	267.55M	321.38M

Line item	2025-03	2025-06	2025-09	2025-12	2026-04	2026-07
Total current assets	434.14M	462.10M	468.42M	782.60M	786.80M	1.12B
Cash & ST investments	106.05M	109.91M	89.22M	380.87M	388.80M	718.65M
Inventory	145.44M	168.07M	179.98M	188.28M	193.14M	192.71M
Total assets	1.39B	1.51B	1.51B	1.81B	1.80B	2.14B
Total current liabilities	146.69M	181.94M	186.86M	212.37M	220.79M	245.88M
Short-term debt	15.58M	15.51M	15.85M	48.15M	50.11M	51.38M
Long-term debt	385.28M	454.04M	445.66M	212.54M	201.01M	188.16M
Total liabilities	615,701,000.00	709,623,000.00	704,335,000.00	492,819,000.00	488,027,000.00	523,107,000.00
Total equity	769.76M	801.45M	801.48M	1.31B	1.31B	1.62B
Retained earnings	288.76M	293.25M	303.91M	321.38M	342.48M	355.02M

Cash flow

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Operating cash flow	89.65M	63.25M	140.24M	94.63M	90.78M	120.08M	158.51M	64.06M
Depreciation & amortization	37.05M	38.28M	38.29M	43.39M	53.16M	46.61M	55.56M	61.93M
Free cash flow	74.99M	52.51M	127.08M	72.45M	69.67M	100.11M	141.35M	48.43M
Dividends paid	--	--	--	--	--	--	--	--
Stock buybacks / issuance	-5.85M	-10.00M	-5.50M	0	-10.00M	0	0	575.11M
Ending cash balance	82.04M	78.94M	125.05M	117.39M	100.11M	105.05M	113.99M	380.87M

Line item	2025-03	2025-06	2025-09	2025-12	2026-04	2026-07
Operating cash flow	31.68M	15.07M	8.50M	8.81M	51.61M	64.93M
Depreciation & amortization	13.56M	15.58M	15.71M	17.08M	14.16M	14.65M
Free cash flow	27.40M	11.68M	4.21M	5.13M	47.47M	57.47M
Dividends paid	--	--	--	--	--	--
Stock buybacks / issuance	-6.16M	0	-14.06M	595.33M	-18.64M	288.45M
Ending cash balance	106.05M	109.91M	89.22M	380.87M	388.80M	718.65M

Returns & efficiency

Line item	2018	2019	2020	2021	2022	2023	2024	2025
ROE %	14.97	10.38	9.96	10.09	13.48	11.65	9.03	5.23
ROA %	7.04	5.13	5.13	4.81	6.00	5.91	4.90	3.37
ROIC %	9.01	6.44	6.26	5.76	7.11	6.80	5.59	3.80
5-year avg ROE %	8.52	12.74	11.60	11.87	11.78	11.11	10.84	9.89
EBIT margin %	12.87	11.48	10.11	11.61	12.48	13.99	13.09	11.90
FCF / sales %	12.21	8.39	21.52	10.25	8.09	11.36	14.89	4.94
Current ratio	2.70	2.26	2.66	2.03	2.56	2.98	2.58	3.69
Quick ratio	1.61	1.30	1.78	1.28	1.45	1.81	1.63	2.71
Debt / assets	29.83	31.70	29.48	40.18	39.43	33.00	33.87	16.71
LT debt / equity	57.06	63.35	49.00	92.15	82.43	58.01	61.11	19.31
Interest coverage	--	--	--	--	--	--	--	--
Revenue CAGR (3Y) %	18.03	17.62	4.25	4.78	11.20	14.29	10.33	4.44
Net income CAGR (3Y) %	11.30	22.83	-9.49	0.82	22.01	17.85	8.39	-10.09
FCF CAGR (3Y) %	39.10	10.11	32.78	-1.14	9.89	-7.64	24.96	-11.41

Line item	2025-03	2025-06	2025-09	2025-12	2026-04	2026-07
ROE %	9.73	8.16	6.84	5.23	5.16	5.11
ROA %	5.05	4.22	3.61	3.37	3.37	3.38
ROIC %	5.73	4.80	4.12	3.80	3.82	3.84
5-year avg ROE %	--	--	--	--	--	--
EBIT margin %	13.28	13.13	12.40	11.90	11.63	11.65
FCF / sales %	14.96	12.32	10.69	4.94	6.82	11.10
Current ratio	2.96	2.54	2.51	3.69	3.56	4.57
Quick ratio	1.88	1.53	1.44	2.71	2.59	3.70
Debt / assets	31.94	33.98	33.50	16.71	16.15	13.31
LT debt / equity	55.47	62.13	60.97	19.31	18.34	14.44
Interest coverage	--	--	--	--	--	--
Revenue CAGR (3Y) %	--	--	--	--	--	--
Net income CAGR (3Y) %	--	--	--	--	--	--
FCF CAGR (3Y) %	--	--	--	--	--	--

✦ Quant Revenue Concentration how this is computed

Lead segment, long tail

Automation Enabling Technologies is the largest reported line at 51.25% of revenue, across 2 reported segments.
Medical Solutions follows at 48.75%, so the top line still matters most but isn’t the whole story.

Revenue breakdown most recent period

Business

Automation Enabling Technologies51.25%

Medical Solutions48.75%

Quote time 2026-10-08 07:14:37 · For reference only, not investment advice and not tailored to your situation.